Tag: aripiprazole
Brexpiprazole as a New Serotonin–Dopamine Receptor Modulator: Considering the Clinical Relevance for Metabolic Parameters and Prolactin Levels
by Masaru Nakamura, MD, PhD, and Takahiko Nagamine, MD, PhD Dr. Nakamura is with the Department of Psychiatric Internal Medicine, Kosekai-Kusatsu Hospital in Hiroshima, Japan. Dr. Nagamine is with the Department of Psychiatric Internal Medicine, Sunlight Brain Research Center in Yamaguchi, Japan. Funding: No funding was provided for this study. Disclosures: The authors have no […]
Atrial Fibrillation and Injected Aripiprazole: A Case Report
by Anthi Stefatos, MD; Julie N. Ha, PharmD; Adrian Baranchuk MD; Ross J. Baldessarini, MD; and Gustavo H. Vázquez MD, PhD Drs. Stefatos and Ha are with the Department of Psychiatry at Queens University in Kingston, Ontario, Canada. Dr. Baranchuk is with the Department of Medicine at Queens University in Kingston, Ontario, Canada. Dr. Baldessarini […]
Aripiprazole for Treatment of Apathy
by Varun Monga, MD, and Prasad R. Padala, MD, MS, FACHE Dr. Monga is from Banner Thunderbird Medical Center, Glendale, Arizona, and Dr. Padala is from the Central Arkansas Veteran’s Healthcare System Geriatric Research Education and Clinical Center, Little Rock, Arkansas. Innov Clin Neurosci. 2015;12(9–10):33–36. Funding: No funding was received for the preparation of this […]
Augmentation of Venlafaxine with Aripiprazole in a Case of Treatment-resistant Excoriation Disorder
by Grant A. Turner, BS; Stephanie Sutton, BA; and Ashish Sharma, MD Mr. Turner is a third year medical student, Ms. Sutton is a fourth year medical student, and Dr. Sharma is Associate Professor of Consult/Liaison Psychiatry; all from University of Nebraska Medical Center, Psychiatry Department, Omaha, Nebraska. Innov Clin Neurosci. 2014;11(1–2):29–31
Letter to the Editor: A case of Paranoid Schizophrenia and severe antipsychotic-induced Parkinson’s Disorder treated with a combination of olanzapine and lurasidone
Oleg V. Tcheremissine, MD, and Danielle Englert, MD Dr. Tcheremissine is Research Director, Department of Psychiatry and Behavioral Sciences, Carolinas Healthcare System; Dr. Englert is Director of Deep Brain Stimulation Program Center for Parkinson’s Disease and Movement Disorders, Department of Neurology Carolinas Healthcare System, Charlotte, North Carolina. Innov Clin Neurosci. 2013;10(9–10):10–14
Letter to the editor: Treatment with Aripiprazole and Levetiracetam in a Subject with Binge Drinking Disorder: A Case Report
Vincenzo M. Romeo, MD; Antonio Bruno, MD, PhD; Umberto Micò, MD, PhD; Rocco A. Zoccali, MD; and Maria Rosaria A. Muscatello, MD, PhD Drs. Romeo, Bruno, Micó, Zoccali, and Musca are with the Section of Psychiatry, Department of Neurosciences, Psychiatric and Anaesthesiological Sciences, University of Messina, Italy; Dr. Romeo is also with Therapeutic Community (C.T., […]
A Prospective Study Comparing the Long-term Effectiveness of Injectable Risperidone Long-acting Therapy and Oral Aripiprazole in Patients with Schizophrenia
by Wayne Macfadden, MD; Yi-Wen Ma, PhD; J. Thomas Haskins, PhD; Cynthia A. Bossie, PhD; and Larry Alphs, MD, PhD Dr. Macfadden was with Ortho-McNeil Janssen Scientific Affairs, LLC, Titusville, New Jersey, at the time of this analysis; Dr. Macfadden currently is Medical Director at Princeton Medical Institute, Princeton, New Jersey; Drs. Ma and Haskins […]
Real-world Data on Atypical Antipsychotic Medication Side Effects
by Elisa Cascade; Amir H. Kalali, MD; Sagar Mehra; and Jonathan M. Meyer, MD Ms. Cascade is Vice President, Quintiles Inc./iGuard, Falls Church, Virginia; Dr. Kalali is Vice President, Global Therapeutic Group Leader CNS, Quintiles, Inc., and Professor of Psychiatry, University of California, San Diego, California; Mr. Mehra is a student intern at iGuard, Falls […]
First Manic Episode in a 55-Year-Old Man After Initiation of Aripiprazole
by Andrew Donohue, DO Dr. Donohue is a Forensic Psychiatrist, Delaware Psychiatric Center, New Castle, Delaware. Psychiatry (Edgemont) 2010;7(4):37–39
